BG-12 Oral Fumarate Phase II

[dignan]

http://home.businesswire.com/portal/sit ... ewsLang=en

Biogen Idec also announced that a Phase II study of BG-12 in patients with relapsing-remitting multiple sclerosis (MS) was initiated in November 2004. The study, being conducted in Europe, is a placebo-controlled, dose-ranging study designed to assess the efficacy and safety profile of BG-12. The primary endpoint of the study will be an MRI measurement of the amount of brain lesion activity at six months. Approximately 250 patients are expected to be enrolled in the study across 10 countries.

About BG-12

In October 2003, Biogen Idec licensed exclusive worldwide rights to develop and market BG-12 from Fumapharm AG, a privately held pharmaceutical company headquartered in Lucerne, Switzerland. BG-12 is an oral fumarate derivative with an immunomodulatory mechanism of action. Biogen Idec is evaluating BG-12 in a range of diseases, including psoriasis and MS.